-
Mashup Score: 0MDS Sessions: Updates on the diagnosis, risk stratification and treatment of lower-risk MDS | VJHemOnc - 1 year(s) ago
Skip to content Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional. Visit …
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0MDS Sessions: Updates on the diagnosis, risk stratification and treatment of lower-risk MDS | VJHemOnc - 1 year(s) ago
Hello, everyone. My name is Sanam Loghavi, I’m a hematopathologist at MD Anderson Cancer Center, and I am thrilled to be joined here today by my colleague and friend, Dr Rami Komrokji from Moffitt Cancer Center. And we’re going to speak to you about lower-risk MDS today. Thank you. It’s a pleasure to be here. So maybe I’ll start kicking off asking you some questions. As you know, I think we have…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 Check out this session featuring experts @Ramikomrokji & @sanamloghavi, who give a wonderful overview of the diagnosis, risk stratification & treatment of lower-risk MDS: 👉 https://t.co/CYktMbNJ91 #MDSsm #HemOnc https://t.co/Dc5erIyzaW
-
-
Mashup Score: 0MDS Sessions: Updates on the diagnosis, risk stratification and treatment of lower-risk MDS | VJHemOnc - 1 year(s) ago
Hello, everyone. My name is Sanam Loghavi, I’m a hematopathologist at MD Anderson Cancer Center, and I am thrilled to be joined here today by my colleague and friend, Dr Rami Komrokji from Moffitt Cancer Center. And we’re going to speak to you about lower-risk MDS today. Thank you. It’s a pleasure to be here. So maybe I’ll start kicking off asking you some questions. As you know, I think we have…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At #SOHO23, we caught up with @sanamloghavi & @Ramikomrokji, who had a great discussion on the diagnosis, risk stratification & treatment of LR-MDS. Watch here: 👉 https://t.co/a33j0leJhy 👈 #MDSsm #HemOnc https://t.co/LdNhZGYsfG
-
-
Mashup Score: 0Smoldering Myeloma | VJHemOnc - 1 year(s) ago
Skip to content Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional….
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥 @BenDiamondMD of @SylvesterCancer caught up with us this afternoon at #IMS23, sharing some interesting insights into the genomic profile of patients with treated high-risk smoldering myeloma. For more updates on SMM, check out: 👉https://t.co/fHzNBUFXZO #MMsm #HemOnc https://t.co/unzdH6Qyed
-
-
Mashup Score: 2The safety of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in R/R MCL - 1 year(s) ago
In this video, Christopher Melani, MD, National Institutes of Health, Bethesda, MD, shares some insights into the ViPOR study (NCT03223610),…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#17ICML | @MelanicjMD shares some insights into the safety of the ViPOR regimen in patients with R/R MCL. Watch here: 🎥 https://t.co/uVP1bS7cDZ @icmlugano #LymSM #HemOnc #ImmunoOnc
-
-
Mashup Score: 0
In this video, Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, briefly discusses how to select between haploidentical transplantation…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
July is #CordBloodAwarenessMonth! 🩸 Check out our interview with @nagler_EBMT, who discusses factors to consider when selecting between haploidentical & cord blood transplantation: 🎥 https://t.co/MaY1JgvX0R #BMTsm #CordBloodAwarenessMonth #HemOnc
-
-
Mashup Score: 5Issues in CAR-T slot allocation in lymphoma and multiple myeloma - 1 year(s) ago
Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, addresses the topic of CAR-T slot allocation in lymphoma and multiple…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out our interview w/ @NicoGagelmann, who briefly discusses challenges with CAR-T slot allocation in lymphoma and multiple myeloma and important factors to consider: 🎥 https://t.co/nC80Pny9qs @EHA_Hematology #EHA2023 #MMsm #LymSM #CARTcell #ImmunoOnc
-
-
Mashup Score: 0
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, shares some highlights from a session on molecular…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#EHA2023 | @jjkiladjian of @HopSaintLouis gives an overview of a session held at this year's meeting which focused on the role of JAK2 VAF testing in MPNs: 👉 https://t.co/tWvmwyTVQX 👈 #MPNsm #HemOnc
-
-
Mashup Score: 0Exploring available third-line treatment options for R/R DLBCL: CAR-T, bispecifics, ADCs & mAbs - 1 year(s) ago
Manali Kamdar, MD, University of Colorado, Aurora, CO, comments on third-line treatment options for patients with relapsed/refractory (R/R) diffuse large…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
What are some third-line treatment options available for patients with R/R #DLCBL? We spoke to Manali Kamdar (@mana1981) at #ASCO23 on the role of #CART therapy, bispecifics, ADCs & mAbs in this setting 👇: https://t.co/3r14XZTVnL @ASCO #LymSM #ImmunoOnc #HemOnc
-
-
Mashup Score: 0Using patient-derived organoids to investigate bispecific T-cell engager immunotherapy in FL - 1 year(s) ago
Joseph Schroers-Martin, MD, Stanford University School of Medicine, Palo Alto, CA, discusses the use of patient-derived lymphoma organoid (PDLO) systems…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We had a lovely interview with @schroersmartin at #17ICML, who shared some insights into the use of patient-derived organoids to investigate T-cell engager immunotherapy in FL. Watch here: 🎥 https://t.co/uznMmSzJKj @icmlugano #LymSM #HemOnc
-
Want to learn more about lower-risk MDS? Check out our recent session with Rami Komrokji & Sanam Loghavi, who discuss: - Diagnosing LR-MDS - Risk stratifying patients - Treatment approaches & more! 👉 https://t.co/5YKTamyXbY #MDSsm #HemOnc https://t.co/Z4TkOSbbAo